Medicare Part D
Substituting generic CV medications for brand-name may confer substantial savings
A study published in Circulation: Cardiovascular Quality and Outcomes found that substituting generic CV medications for brand-name medications in the Medicare Part D prescription program may result in substantial cost savings.
U.S. House votes to cap insulin cost at $35 per month
The U.S. House of Representatives approved a bill on November 19 that would cap insulin prices at $35 per month for Americans with diabetes.
Authorized generic drugs ‘insufficient’ to improve affordability in Medicare Part D
Authorized generic drugs for insulin and direct-acting antiviral agents may lower out-of-pocket spending for patients but are unlikely to provide savings for Part D plans or Medicare, data show.
BLOG: Game on: Cequa jumps into Medicare Part D
Ladies and gentlemen, we have ourselves a contest here!
Requesting generic drugs could save Medicare program $1.7 billion
By substituting branded drugs requested by prescribers for generic versions, Medicare could have saved $997 million and patients could have saved $161 million in 2017, according to research published in JAMA Network Open.
Thousands of Medicare plans apply to Part D savings model capping insulin costs at $35
More than 1,750 standalone Medicare plans have applied to participate in an enhanced Part D Senior Savings Model that caps out-of-pocket insulin costs at $35 for a 30-day supply for the 2021 plan year, according to a press release from CMS.
Annual price hikes for RA biologics greatly 'eroded' Medicare Part D cost savings
Despite large reductions in out-of-pocket spending from 2010 to 2011, Medicare Part D beneficiaries who receive biologics for rheumatoid arthritis saw more than half of those savings lost by 2019 due to annual list price increases, according to data published in JAMA Network Open.
Lilly introduces $35 insulin copay card in response to COVID-19
Eli Lilly announced on Tuesday it will introduce a $35 insulin copay card for anyone with commercial insurance and those without insurance in response to the economic crisis caused by COVID-19, according to an industry press release.
Akebia sues after CMS removes Auryxia from Medicare Part D coverage
Akebia Therapeutics has filed a lawsuit against CMS for rescinding Medicare Part D coverage of the company’s FDA-approved iron drug Auryxia and for the agency’s decision to impose a prior authorization requirement for use of the drug to treat hyperphosphatemia.
Medicare could save 90% on hypertension medications by switching to generic drugs
Medicare could have saved nearly 90% of spending on angiotensin converting enzyme inhibitors and angiotensin-II-receptor blockers in 2016 and 2017 through generic substitute or therapeutic interchange, according to study results published in JAMA Internal Medicine.